Presolicitation
Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing
26-008155
National Institutes of Health, National Institutes of Health Olao. In-Vitro Diagnostic Substance Manufacturing.
Awarded
Fisher Scientific Company L.L.C.
$24,259.60 obligated so far on USAspending
Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities
This one was awarded in 2026
13 like it are open now in in-vitro diagnostic substance manufacturing
- Reagents and consumables for Roche immunostainers
National Institutes of Health, National Institutes of Health Olao
Combined synopsis and solicitationNAICS 325413Anywhere in the US75N98027Q00026Closes in 15 daysNov 16 - NOI - DNA Sequencing of Bone Marrow Failure Syndro
National Institutes of Health, National Institutes of Health Olao
Combined synopsis and solicitationNAICS 325413Anywhere in the US75N98027Q00027Closes tomorrowNov 2 - HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Department of Veterans Affairs, 262-Network Contract Office 22
Sources soughtNAICS 325413Anywhere in the US36C26227Q0046Closes tomorrowNov 2
Description
As published on SAM.gov.
NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT
Title: Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing
Notice ID (POTS): 26-008155
Product Service Code (PSC): 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits, and Sets
NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing
Place of Performance: National Institutes of Health
Clinical Center
Bethesda, MD 20892
Notice
The National Institutes of Health (NIH) Clinical Center intends to award a sole-source firm-fixed-price purchase order to Fisher Scientific for validated reagents and consumable materials required by the Center for Cellular Engineering (CCE) to manufacture FDA-regulated cell-based therapies for use in NIH clinical trials.
Requirement
The Center for Cellular Engineering (CCE) uses these reagents and consumable materials in the manufacture of FDA-regulated cell-based therapies for patients enrolled in clinical trials at the NIH Clinical Center. All materials have been validated for use in CCE manufacturing processes to ensure they consistently meet the quality standards required to produce safe and effective cell therapy products. Additionally, each material has been reviewed and approved by the CCE Quality Assurance Department, and substitution with alternative products would require extensive revalidation of manufacturing processes, resulting in increased costs, schedule delays, and potential impacts to patient care.
Sole-Source Rationale
The required reagents and consumables have been validated and approved for use in CCE manufacturing processes. Substituting alternate materials would require extensive requalification, increase costs, delay production, and negatively affect patient care. Fisher Scientific is the only vendor capable of providing the required validated materials and supporting documentation necessary for FDA-regulated manufacturing.
Authority
The intended sole-source acquisition is authorized under Federal Acquisition Regulation (FAR) 13.106-1(b)(1)(i), which permits solicitation from a single source when the Contracting Officer determines that only one source is reasonably available for an acquisition not exceeding the Simplified Acquisition Threshold.
Capability Statements
This notice is not a request for quotations or proposals. However, responsible sources that believe they can satisfy the Government's requirement may submit a written capability statement. The Government will evaluate all capability statements received; however, the determination not to compete this requirement remains solely within the Government's discretion.
Submission Instructions
Capability statements shall reference POTS 26-008155 and must be submitted electronically no later than August 13, 2026, at 6:00 P.M. Eastern Time (ET).
Point of Contact
Shasheshe Goolsby
Team Leader
Hospital and Laboratory Support Division
Office of Acquisitions and Logistics Management
National Institutes of Health
Email: shasheshe.goolsby@nih.gov
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Fisher Scientific Company L.L.C.
- UEI
- HE7NJQGP4ED6
- CAGE
- 22527
- Vendor location
- Pittsburgh, PA
- Contract
- 75N98026P01364, purchase order
- Obligated
- $24,259.60
- Actions
- 1 between August 20, 2026 and August 20, 2026
- Competition
- Competed Under SAP, 1 offer received
- Set-aside reported
- No Set Aside Used.
- Described as
- 26-008155 Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing
- Match
- solicitation number 26008155 equals the FPDS solicitation identifier; same awarding office 75N980 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
August 4, 2026
Presolicitation
Due August 13, 2026 at 6:00 PM EDT. SAM.gov, notice 6300eb88fb754bab906800057e4f1f43
1 revisions on SAM
- August 4, 2026: publish, presolicitation
Points of contact
- Shasheshe Goolsbyshasheshe.goolsby@nih.gov3018274879